Construction and Practice of Clinical Comprehensive Evaluation System for Sodium-Glucose Linked Transporter 2 Inhibitors in the Treatment of Heart Failure
OBJECTIVE:To construct a clinical comprehensive evaluation system for sodium-glucose linked transporter 2(SGLT2)inhibitors in the treatment of heart failure,and to perform an empirical evaluation,so as to provide reference for clinical value in heart failure treatment.METHODS:Through literature analysis,expert interviews,safety signal mining,and the Delphi method,combined with relevant documents and guidelines,a comprehensive evaluation system for the clinical value of SGLT2 inhibitors in heart failure treatment was developed,focusing on pharmaceutical characteristics,effectiveness,safety,cost-effectiveness,other attributes,and accessibility.A qualitative and quantitative data integration analysis and comprehensive judgment of SGLT2 inhibitors were conducted from multiple dimensions.RESULTS:A scientific,objective and quantifiable clinical comprehensive evaluation system for SGLT2 inhibitors in the treatment of heart failure was established.After weighting and synthesizing the evaluation results across various dimensions,dapagliflozin obtained a score of 83.14 points,empagliflozin scored 78.36 points,ertugliflozin scored 73.70 points,and canagliflozin scored 70.18 points.CONCLUSIONS:Based on the current evidence,different SGLT2 inhibitors exhibit varying advantages in the treatment of heart failure.This evaluation system and empirical results can provide scientific,effective,safe and economical evidence for the clinical use of SGLT2 inhibitors in heart failure.
Sodium-glucose linked transporter 2 inhibitorsHeart failureClinical comprehensive evaluationClinical practice value
万方数据
维普
